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1 Summary 
Atopic diseases as hav fever, allergic asthma and atopic dermatitis are of increasing 
prevalence. It is estimated that moulds account for around 20% of atopic diseases in 
atopic individuals and up to 6% in the general population. Cladosporium herbarum 
(Cla h), together with Alternaria alternata (Alt a) are two of the most important 
allergenic moulds.  Diagnosis of atopic diseases is based on clinical history, skin 
tests, detection of specific serum IgE and provocation tests with the suspected 
allergen. Usually, extracts purified from raw material are used for these tests. Due to 
the included mixture from proteins and various extraction procedures, often only a 
limited standardization and purity is achievable. Recombinant allergens were found to 
be a very specific, reliable and safe tool for the diagnosis of mould allergic diseases 
and able to elicit allergic reactions in vivo. 
In our study we investigated in a clinical trial of 29 mould allergic patients the use of 
selected recombinant mould allergens in skin prick tests (SPT), in comparison with 
natural mould allergen extracts. SPT were performed with recombinant allergens of 
Cla h and Alt a (rAltNTF, rClaNTF, rAltMtDH, rClaMtDH, rAlta1, rClaTcTPEn) and 
with natural allergen extracts of the two moulds. Skin tests with the recombinant 
allergen rAlta1 were highly specific and detected more patients than skin tests with 
the allergen extracts. We were able to confirm that Alta1 is a major allergen of Alt a. 
In spite of the large number of allergens in Alt a, it is likely that a combination of Alta1 
with a small number of other recombinant allergens could be sufficient to correctly 
diagnose Alt a sensitised patients with a high sensitivity and specificity. The other 
recombinant allergens that were investigated in our study, showed only in a very 
limited number of patients positive SPT and seem to be of lower importance.  None 
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of the 17 controls showed a positive SPT. There were no side-effects recorded 
relating to the use of recombinant allergens in patients and controls. 
Ongoing and future studies will have to determine the use of other recombinant 
allergens and also the therapeutic use of recombinant allergens for the specific 
immunotherapy of allergic diseases. However our findings strongly support the use of 
recombinant proteins in the diagnostic work up, especially for Alt a - related allergies 
and for the in vivo use. 
 
 
Abbreviations  
Alt a   Alternaria alternata 
Cla h  Cladosporium herbarum 
MtDH  Mannitol dehydrogenase 
NTF2  Nuclear transport factor 2 
r  Recombinant  
RCA  Allergic rhinoconjunctivitis 
SPT  Skin prick test 
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2 Introduction 
2.1 Overview 
Allergy is a hypersensitive response of the immune system to inhaled or ingested 
proteins, the allergens.  In the past decades an increased prevalence of allergic 
diseases has been reported (1). Up to 20% of the population of the industrialized 
world are affected. Allergens constitute proteins from animals and plant sources (2, 
3). Exposure to allergens results in the induction of IgE antibody, which is thought to 
be the central mechanism in the induction of an allergic reaction of the so-called 
immediate type.  Allergic (extrinsic) asthma, allergic rhinitis, food allergy, drug allergy, 
insect sting reactions and to some extent atopic dermatitis and urticaria are classical 
IgE-associated allergies. The knowledge of a causing allergen often allows the 
avoidance of an allergen contact and has therefore a strong preventive character.  
The diagnosis of allergic diseases is based on a profound and well-structured clinical 
history and the detection of allergen-specific IgE results. The classical methods 
therefore are skin tests, detection of specific IgE in the serum and challenge of the 
affected organ by so-called provocation test.  
Fungal allergy constitutes 25% to 30% of all allergic asthma cases (4, 5). Among the 
outdoor allergens, fungal spores, together with tree and grass pollen constitute major 
representatives. Furthermore, fungal spores are besides proteins from dust mite, 
cockroach and animal dander important indoor allergens as well. The prevalence rate 
of fungal allergy is estimated to be around 20% in atopic individuals and up to 6% in 
the general population (6-8). Attempts to establish the exact prevalence rate of fungal 
sensitation showed a vast variability what is ascribed to differences in the studied 
population, the tested species of fungi and the fungal extracts used (7).  
   
6 
 
Tens of thousands of fungal species are described currently. Until now, more than 80 
genera of fungi have been associated with respiratory allergy, including yeasts and 
moulds (8). Fungi are eukaryotic, unicellular to multicellular, usually spore-bearing 
organisms. The term mould is often used synonymously with the term fungi, but 
actually describes a subgroup of mycelial fungi. Moulds occur ubiquitously in all 
continents and are present in all types of environment. The concentration of fungal 
spores in the environment depends on many factors, including climate and 
vegetation (9). Mould spores are present in outdoor air and inside the house, 
preferentially in bathrooms and basements, as well as in new habitations, in 
particular in case of exaggerated isolation and bad aeration of the room. Indoor 
spores constitute either form outdoor air or from moulds growing indoors. The types 
of moulds that are growing indoors and their prevalence depend on moisture, 
ventilation, presence or absence of carpets, pets, and houseplants (10).  
Exposure to allergenic moulds may lead to IgE-mediated rhinitis and asthma, atopic 
dermatitis, or very rarely to systemic reactions such as urticaria or anaphylactic 
shock. Clinically, the presenting symptoms are sneezing, nasal discharge, coughing, 
wheezing, and shortness of breath, with evidence of reversible airway obstruction, 
rarely assocaited with other symptoms such as urticaria, angioedema, and even 
anaphylaxis. 
 
2.2 Cladosporium herbarum and Alternaria alternata 
Cladosporium herbarum (Cla h), together with Alternaria alternata (Alt a) are two of 
the most important allergenic moulds.  A European multicenter study showed that the 
prevalence of Cla h and Alt a sensitisation varies widely in the different climatic zones 
of the world. It was demonstrated that 3 up to 20% of all allergic patients tested, 
showed positive responses to Cla h and / or Alt a in skin prick tests (11). Sensitised 
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patients were in most cases tested positive to several moulds. Monosensitization to 
just one mould species is found rarely. Whereas Cla h dominates in cooler climates, 
Alt a grows preferentially in warm and humid environments.  
 
2.3 Diagnostics in mould allergy and recombinant allergens 
Besides clinical history, diagnosis of allergy is based on skin tests, provocation tests 
and in vitro investigations for determination of specific IgE. Skin tests are next to 
clinical history the basic tool in each allergological work-up. They are easily to 
perform and do allow a visible result within a few minutes. The in vitro tests most 
often used to determine specific serum IgE are radioallergosorbent test (RAST) (12), 
cellulose-absorbent paper test (CAP) (13, 14), and enzyme-linked immunosorbent 
test (ELISA). ImmunoCAPs are the most widely used method for the determination of 
allergen-specific IgE. In this test, allergens are immobilized onto cellulose solid phase 
by covalent binding. The coupling concentration is usually adjusted to attain a linear 
measurement range and a background below 0.35kU/l. Specific IgE in the serum is 
bound on allergen disks and is detected by colorimetry. 
For skin tests, provocation tests and in vitro investigations, natural allergen extracts 
are used. These extracts are complex mixtures of relevant allergenic proteins, but 
contain also many non-allergenic substances, including other proteins and 
carbohydrates (15). Mould allergens are usually proteins, polysaccharides, or 
glycoproteins (16). Most allergen preparations derived from complex allergenic 
sources like moulds are still not yet available as internationally recognized, 
standardized products. Extracts derived from natural sources may vary in allergen 
composition and content. This was demonstrated in studies that showed a low 
correlation between skin test reactivity and reactivity of specific serum IgE using 
natural extracts (17). It has been difficult to obtain adequate quantities of fungal 
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extracts that are qualitatively and quantitatively reproducible in terms of allergen 
content. Furthermore there is variability in allergen content and in the amount of 
allergen produced from fungal sources because the quality of the extracts is 
influenced by many factors, including quality of the starting raw material, extraction 
procedure, protease content and storage conditions (18). Moreover, natural allergen 
extracts can be contaminated with allergens from other sources (19). Standardization 
of allergen extracts is therefore essential to avoid variation in sensitivity and 
specificity of allergy diagnoses (20).  
The complexity and the variability of the fungal allergens have complicated the 
process of obtaining purified and standardized antigens. Considerable research has 
been directed to purify relevant antigens from fungi, but none of the applied methods 
has yielded relevant allergens useful in the diagnoses of mould allergy. However, 
recently, using molecular biology to clone and express relevant antigens from 
moulds, a possibility for standardization has developed (21). The resulting 
recombinant allergens represent highly pure protein preparations free of 
contaminants deriving from natural allergenic sources. Many allergens have been 
cloned, and the proteins expressed. Currently, about 100 fungal allergens have been 
approved by the International Allergen Nomenclature Committee (22). The cloning of 
allergens consists of the isolation and purification of messenger RNA from actively 
growing cultures (23). The purified messenger RNA is subsequently reverse 
transcribed to obtain cDNA and finally the desired DNA fragments are cloned and 
amplificated by polymerase chain reaction (PCR). The expression of the protein is 
induced in bacterial host, usually in Escherichia coli (Figure 1). 
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Figure 1: Production of recombinant allergens in E. coli 
 
 
 
Although cloning and characterization of single allergens may be time consuming, the 
advantages are manifold. Recombinant allergens can be carefully quantified in terms 
of protein concentration, and IgE reactivity would not be interfered by irrelevant 
proteins, macromolecules, or enzymes (24, 25). Therefore, recombinant allergens 
can be used as a ‘golden standard’ for both in vitro and in vivo tests, allowing  
objective comparisons of test results obtained in different studies and with different 
methods. Furthermore, recombinant allergens are powerful reagents to study the 
mechanisms involved in allergic reactions (26) and to study structure-function 
relationships (27). 
Skin testing with recombinant allergens offers a highly specific and safe diagnostic 
tool to elucidate patient- and disease-specific sensitization patterns. Mostly due to 
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ethical and legal restrictions regulating the use of recombinantly produced proteins in 
humans, skin tests with recombinant Allergens have been rarely performed. The first 
skin tests with recombinant Allergens have been described in 1992 (28), many years 
after cloning of the first allergen from house dust mite (29). Recently, more and more 
work has been done in this direction and recombinant allergens pollen, mites, 
different fungi, bee venom, various foods and latex have been evaluated in skin tests 
as reviewed recently (30). 
 
2.4 Aims of the study 
The aim was to contribute more data about the diagnostic reliability of recombinant 
allergens for clinical applications.  
The goal was to evaluate the specificity, sensitivity and safety of selected 
recombinant mould allergens in comparison with natural mould allergen extracts by 
skin testing. 
The patients in our study were sensitised to natural allergen extracts of Cla h and / or 
Alt a. As mentioned earlier, moulds are complex allergenic sources that contain large 
amounts of IgE-binding molecules, covering many different species-specific and 
cross-reactive structures. Several IgE-binding structures of Cla h and Alt a have been 
cloned and characterized to date (30-38). We utilized the following recombinant 
allergens: 
rAlta1 
This 30kD Protein reacts with IgE of the majority of Alt a - sensitized patients. It is a 
secreted protein, which presumably resides in the periplasmatic space of Alt a cells. 
Up to now, extensive homology searches revealed no Alta1 homolog from other 
species and thus there is no clue to the biological function of this major allergen (32, 
36). 
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rAltNTF / rClaNTF 
Nuclear Transport Factor 2 (NTF2) is a protein with a molecular weight of 
approximately 15kD. It is essential for maintaining cellular nuclear transport and cell 
viability. NTF2 represents a cross-reactive fungal allergen. Alt a and Cla h show a 
sequence identity of 64% (35). 
r Alt MtDH / r Cla MtDH 
Mannitol dehydrogenase is a recently cloned, 28kD Protein (37, 38). It is a NADP-
dependent, cytoplasmatic protein which is abundant in vegetative cells of moulds. It 
has been shown that mannitol dehydrogenase is a stress-inducible protein (39, 40). 
Its physiological importance may be seen in the interaction between the mould and 
its environment. There is evidence that mannitol dehydrogenase is a first major 
allergen of Cla h (37) and the second most important allergen of Alt a that has been 
identified so far (38). Cross-inhibition ELISA showed that MtDH is cross-reactive 
between Alt a and Cla h and that in addition to shared IgE-epitopes, there also exist 
mould-specific epitopes as no complete cross-inhibition could be achieved (38). 
r Cla TcTPEn 
The translationally controlled tumor-associated proteins (TCTPs) are a highly 
conserved and abundantly expressed family of eukaryotic proteins that are implicated 
in both cell growth and the human acute allergic response but whose intracellular 
biochemical function has remained elusive (41). 
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3 Patients, Materials and Methods 
3.1 Patients and controls 
Three different groups of participants  were included into the study. 
- Group 1: mould allergic patients (29 pts) 
- Group 2: allergic patients sensitized to inhalant allergens but not to moulds (6 pts) 
- Group 3: healthy, non-allergic controls (11 individuals) 
 
Group 1 included 29 patients with typical symptoms of inhalant allergies and 
sensitation against moulds. Diagnosis of mould allergy was based on elevated 
specific IgE serum levels to Cla h and / or Alt a, determined by CAP-RAST test 
results (ImmunoCAP Pharmacia) together with a clinical history of recurrent rhinitis 
(possibly also additional conjunctivitis and / or asthma). All patients showed stable 
lung functions. 
 
Group 2 included 6 patients with a history of allergic symptoms such as saisonal 
rhinoconjuncitivitis and asthma. All showed sensitizations against common inhalant 
allergens such as mites, pollen or animal dander but not to moulds, which was shown 
by a negative screening test for fungal allergens (Mx1).  
 
Group 3 included 11 healthy, non-allergic controls. Individuals were defined by the 
absence of a history of allergic symptoms and not detectable specific IgE against 
common inhalant, food and fungal allergens (negative screening tests by CAP RAST 
for Sx1, Mx1, Fx5).  
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Characteristics of patients and controls are displayed in tables 1 and 2. 
Table 1: Characteristics of patients 
 
 
Table 2: Characteristics of controls 
 
 
 
The patients were recruited from our allergy unit on the basis of positive CAP-RAST 
test results which where obtained during the years 2000-2004.  
During the study, patients were not allowed to use either antihistamines or topical or 
systemic steroids, starting at least one week before the investigations. 
number of patients included 29 
mean age (range) 35 (16-61) 
gender m/f 15/14 
CAP m2 (>0.5 kU/l) 17/29 (59%) 
CAP m6 (>0.5 kU/l) 26/29 (90%) 
 allergic controls healthy controls 
number of controls included 6 11 
mean age (range) 31 (23-57) 32 (26-62) 
gender m/f 4/2 5/6 
Sx1 (<0.35 kU/l) 0/7 (0%) 11/11 (100%) 
Mx1 (<0.35 kU/l) 7/7 (100%) 11/11 (100%) 
Fx5 (<0.35 kU/l) 7/7 (100%) 11/11 (100%) 
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The study was approved by the Ethical Committee of the University of Zurich. A full 
oral and written explanation of the procedure was given to the patients and controls. 
All patients and controls gave oral and written informed consent before testing. 
 
3.2 SPT with extracts and recombinant allergens 
SPT were performed with commercial extracts and recombinant allergens from Cla h 
and Alt a (ALK Amersham, Denmark). Sodium chloride (0.9%) and histamine 
hydrochloride (ALK Amersham, Denmark) served as negative and positive controls 
respectively. All SPTs were performed twice on the volar forearm and applied in the 
opposite directions. Twenty microliters of the allergen solutions were used per test. 
SPTs were read after 20 min. Wheals and flares were penmarked and then 
transferred with scotch tape to a paper. Practical realisation of SPT and 
documentation is displayed on figure 2. SPT was considered positive when a mean 
diameter of  4 mm was achieved. Only patients with a SPT to negative control with 
0.9% sodium chloride with a wheal diameter below 1 mm were included in the study. 
Figure 2: practical realisation of SPT and documentation 
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3.3 Determination of allergen-specific IgE  
From all patients and controls, specific IgE to natural extracts of Cla h and Alt a were 
determined by the Immuno-CAP System. Results are displayed in table 3a. 
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4 Results 
4.1 SPT with extracts and recombinant allergens 
Of 29 patients with mould-allergy, 25 patients showed positive skin test reactions 
(86%). 4 patients showed no reactions to mould allergens (14%). Of the 25 patients 
with positive skin test reactions, 22 patients reacted either to allergens of Cla h or to 
allergens of Alt a (7 patients and 15 patients respectively). 3 patients showed positive 
skin tests to allergens of both of the moulds. Positive skin tests with Cla h allergens 
were achieved with commercial extracts (10 patients), with rClaMtDH (1 patient) and 
with rClaNTF (1 patient). We found no positive reactions with rClaTcTPEn.  
Positive skin tests with Alt a allergens were achieved with commercial extracts (13 
patients), with rAlta1 allergen (17 patients), and with rAltNTF (1 patient). No positive 
results were found with rAltMtDH.  
In the control groups, no positive skin tests with commercial mould extracts or 
recombinant allergens were achieved. To mention is that a primarily in the healthy 
control group assigned person showed a clearly positive skin prick reaction (8mm) to 
rAlta1 allergen. This person negated any allergic symptoms but was excluded from 
the healthy control group because screening CAP-RAST Tests indicated sensitation 
to several antigens (Sx1 0.71kU/l, Mx1 0.37kU/l, m6 0.42kU/l). 
All results are displayed in tables 3a and 3b.  
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Table 3a: In vivo and in vitro pattern of sensitization to fungal Allergens 
 
Nr. History 
SPT Cla  
(mm) 
SPT Alt 
 (mm) 
SPT rAlta1 
 (mm) 
other SPT 
(mm) 
CAPm2 
(kU/l) 
CAPm2 
(kU/l) 
1 RCA negative 4.0 10.5 negative 3.30 27.40 
2 RCA negative 4.0 9.0 negative 1.59 15.60 
3 RCA 4.0 negative negative negative 0.47 1.33 
4 RCA 4.0 5.0 12.0 negative 11.40 27.20 
5 RCA 7.0 negative negative negative 9.63 <0.35 
6 RCA negative negative negative negative 16.80 49.20 
7 RCA 7.0 negative negative negative 13.10 <0.35 
8 RCA 5.0 negative negative negative 6.08 <0.35 
9 RCA negative negative 7.0 negative 1.19 12.60 
10 RCA negative negative negative negative 0.83 0.72 
11 RCA negative negative negative negative 1.04 2.20 
12 RCA negative negative 10.5 negative 1.73 43.70 
13 RCA 7.5 negative negative rClaMtDH 11.5 29.50 0.96 
14 RCA 7.0 8.0 10.0 negative <0.35 4.40 
15 RCA negative negative negative negative <0.35 2.45 
16 RCA negative 5.0 12.5 negative <0.35 1.26 
17 RCA negative 4.0 10.5 negative <0.35 4.45 
18 RCA negative 4.0 12.0 negative 1.77 18.90 
19 RCA negative 5.0 10.0 negative <0.35 3.97 
20 RCA negative 5.5 9.5 negative 2.44 18.10 
21 RCA negative 4.5 12.5 negative <0.35 6.14 
22 RCA 5.0 negative negative negative 13.10 0.53 
23 RCA 4.0 5.0 8.5 negative 1.01 10.80 
24 RCA negative negative 11.0 negative <0.35 10.20 
25 RCA negative 5.0 10.0 negative <0.35 27.50 
26 RCA negative negative 10.5 negative <0.35 1.04 
27 RCA 4.0 negative negative negative 1.36 1.89 
28 RCA negative negative 8.5 negative <0.35 1.55 
29 RCA negative 5.0 negative rCla/AltNTF4.0 <0.35 0.66 
        
30 healthy negative negative negative negative <0.35 <0.35 
31 healthy negative negative negative negative <0.35 <0.35 
32 healthy negative negative negative negative <0.35 <0.35 
33 healthy negative negative negative negative <0.35 <0.35 
34 healthy negative negative negative negative <0.35 <0.35 
35 healthy negative negative negative negative <0.35 <0.35 
36 healthy negative negative negative negative <0.35 <0.35 
37 healthy negative negative negative negative <0.35 <0.35 
38 healthy negative negative negative negative <0.35 <0.35 
39 healthy negative negative negative negative <0.35 <0.35 
40 healthy negative negative negative negative <0.35 <0.35 
        
41 RCA negative negative negative negative <0.35 <0.35 
42 RCA negative negative negative negative <0.35 <0.35 
43 RCA negative negative negative negative <0.35 <0.35 
44 RCA negative negative negative negative <0.35 <0.35 
45 RCA negative negative negative negative <0.35 <0.35 
46 RCA negative negative negative negative <0.35 <0.35 
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Table 3b: In vivo pattern of sensitization to recombinant fungal allergens 
 
 
Nr. 
SPT 
Cla  
(mm) 
SPT 
Alt 
(mm) 
SPT 
rAlta1 
 (mm) 
SPT 
rAltNTF 
(mm) 
SPT 
rClaNTF 
(mm) 
SPT 
rAltMtDH 
(mm) 
SPT 
rClaMtDH 
(mm) 
SPT 
rClaTcTPEn 
(mm) 
SPT 
humTcTp 
(mm) 
1 neg 4.0 10.5 neg neg neg neg neg neg 
2 neg 4.0 9.0 neg neg neg neg neg neg 
3 4.0 neg neg neg neg neg neg neg neg 
4 4.0 5.0 12.0 neg neg neg neg neg neg 
5 7.0 neg neg neg neg neg neg neg neg 
6 neg neg neg neg neg neg neg neg neg 
7 7.0 neg neg neg neg neg neg neg neg 
8 5.0 neg neg neg neg neg neg neg neg 
9 neg neg 7.0 neg neg neg neg neg neg 
10 neg neg neg neg neg neg neg neg neg 
11 neg neg neg neg neg neg neg neg neg 
12 neg neg 10.5 neg neg neg neg neg neg 
13 7.5 neg neg neg neg neg 11.5 neg neg 
14 7.0 8.0 10.0 neg neg neg neg neg neg 
15 neg neg neg neg neg neg neg neg neg 
16 neg 5.0 12.5 neg neg neg neg neg neg 
17 neg 4.0 10.5 neg neg neg neg neg neg 
18 neg 4.0 12.0 neg neg neg neg neg neg 
19 neg 5.0 10.0 neg neg neg neg neg neg 
20 neg 5.5 9.5 neg neg neg neg neg neg 
21 neg 4.5 12.5 neg neg neg neg neg neg 
22 5.0 neg neg neg neg neg neg neg neg 
23 4.0 5.0 8.5 neg neg neg neg neg neg 
24 neg neg 11.0 neg neg neg neg neg neg 
25 neg 5.0 10.0 neg neg neg neg neg neg 
26 neg neg 10.5 neg neg neg neg neg neg 
27 4.0 neg neg neg neg neg neg neg neg 
28 neg neg 8.5 neg neg neg neg neg neg 
29 neg 5.0 neg 4.0 4.0 neg neg neg neg 
          
30 neg neg neg neg neg neg neg neg neg 
31 neg neg neg neg neg neg neg neg neg 
32 neg neg neg neg neg neg neg neg neg 
33 neg neg neg neg neg neg neg neg neg 
34 neg neg neg neg neg neg neg neg neg 
35 neg neg neg neg neg neg neg neg neg 
36 neg neg neg neg neg neg neg neg neg 
37 neg neg neg neg neg neg neg neg neg 
38 neg neg neg neg neg neg neg neg neg 
39 neg neg neg neg neg neg neg neg neg 
40 neg neg neg neg neg neg neg neg neg 
          
41 neg neg neg neg neg neg neg neg neg 
42 neg neg neg neg neg neg neg neg neg 
43 neg neg neg neg neg neg neg neg neg 
44 neg neg neg neg neg neg neg neg neg 
45 neg neg neg neg neg neg neg neg neg 
46 neg neg neg neg neg neg neg neg neg 
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4.2 Determination of allergen-specific IgE  
The results performed with the Immuno-CAP System are displayed in table 3a. As 
being one of the inclusion criteria, patients had either elevated IgE-levels for Cla h or 
Alt a. 
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5 Discussion 
Mould allergy is a not very frequent but nevertheless clinically relevant problem in 
about 3 to 6% of the population. However, diagnosis of fungal allergy remains a 
difficult task. The complexity and the variability of the fungal allergens don’t allow to 
obtaining purified and well-standardized extracts. Considerable efforts have been 
directed to purify relevant antigens from fungi, but none of the applied methods has 
yielded relevant allergens useful in the diagnosis of mould allergy. However, 
recombinant allergens with well standardized and highly pure allergenic proteins are 
a possible tool to improve the diagnosis of mould allergies. The detection of in vitro 
IgE-binding with recombinant allergens not necessarily leads to allergenicity in vivo, 
due for example to incorrect folding or tertiary structure. Thus we wanted to 
investigate the in vivo reactivity of such single recombinant fungal allergens in mould 
allergic patients by performing skin prick tests. 
We could examine only a relatively limited number of patients due to the fact that 
relevant sensitization against moulds is rather rarely detectable. We recruited our 
patients from the basis of positive CAP-RAST test results that were obtained during 
allergy screening tests. The limited number of recruitable patients is due to various 
reasons:  
- in general, allergy to moulds affects only about 3-6% of the population 
compared to up to 18% of the population suffering from pollinosis 
- the symptoms of mould allergy are often not very clear attributable to a certain 
season or place and therefore missed more often 
- the sensitivity and specificity of the current diagnostic tools (Skin tests and 
specific IgE) are very low, so fungal allergy can be missed quiet easily 
 
   
21 
 
In our study we were able to confirm the importance of the major allergen Alta1 in Alt 
a - sensitised patients. 
More than 90% of the patients with positive skin tests to commercial extracts were 
tested positive to recombinant Alta1 - allergen. According to the literature and now 
demonstrated by our findings, it seems to be by far the most important antigen of Alt 
a (32, 36). The other recombinant Alt a allergen that showed a positive SPT, rAltNTF, 
is likely to be less important, since only one single patient had a positive SPT. Thus 
we postulate that it is a minor allergen of Alt a. Surprisingly, we found no positive skin 
reactions with rAltMtDH. We expected positive results because recent in vitro 
investigations (IgE-ELISA and immunoblots) showed that MtDH is recognized by 
41% of Alt a - allergic patients (38).  Possible reasons for these divergent results are 
discussed later. 
Interestingly, more serological Alt a - sensitized patients reacted in skin tests with the 
recombinant protein Alta1 than with the commercial extract: 12 patients were tested 
positive both for rAlta1 and extract, 5 patients reacted solely to rAlta1 and only 1 
patient reacted solely to the extract. There were no positive skin tests in patients or 
controls. The findings underline on one side the very high specificity of the 
recombinant allergens. On the other side, in the case of Alt a with a rather 
heterogenous commercial extract, and with rAlta1 seeming to be the most important 
allergen, we found an even higher sensitivity of the recombinant allergen compared 
to the commercial extract. 
In spite of the large number of allergens in Alt a, it is most  likely that a combination of 
rAlta1 with a small very limited number of other recombinant allergens of Alt a is 
sufficient to correctly diagnose sensitised patients with a sensitivity and a specificity 
superior to those obtained with the nowadays available commercial extracts.  
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The same has been shown by Asturias et al. in 41 patients using natural Alta1 and 
two different forms of recombinant Alta1 (42). 
In other studies it  has been found that the use of recombinant allergens for skin tests 
gives an excellent specificity which often reaches 100% (18). Knowing that different 
allergens of a species can be responsible to elicit allergy, it is understandable that 
the sensitivity of skin tests with single recombinant allergens is generally lower than 
those obtained with commercial extracts. An increasing numbers of recombinant 
allergens will therefore raise the sensitivity of the diagnosis. The minor allergen 
rAltNTF may contribute to reduce the number of structures required for such a 
diagnostic test (35).  
Our results in the investigations with allergens of Cla h were not as meaningful as the 
results with allergens of Alt a. Positive SPTs were achieved in only one patient with 
rClaNTF and in another patient with rClaMtDH. Regarding the results of SPTs in our 
study, these two allergens seem not to be major allergens of Cla h. A major allergen 
like Alta1 in Alt a has not been found until now. However, recently published 
investigations presented cloning, production and characterization of ClaMtDH stated 
that ClaMtDH is a major allergen of Cla h, since it could be shown that more than 
50% of the Cla h allergic patients displayed specific IgE-reactivity with the pure 
rClaMtDH (37). The reason for the discrepancy between skin tests and in vitro results 
might be due to incorrect folding of the molecule or lack of glycosilation that does not 
occur in recombinant allergens produced in E. coli (43).  
Assuming, ClaMtDH would be a major allergen of Cla h, it is likely that the 
combination of allergens that are sufficient to diagnose patients sensitised to Cla h 
has to be much larger than the combination of Alt a allergens, since the incidence of 
sensitization to ClaMtDH seems not to be as frequent as the incidence of 
sensitization to Alta1. 
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SPT with recombinant allergens proved to be safe as no adverse side effects, neither 
allergic nor toxic, have been observed in our study. This is also observed in more 
than 45 other studies, where no serious adverse effects due to skin tests with 
recombinant allergens occurred in more than 1400 patients tested (18). 
 
To conclude, the major advantages of recombinant allergens compared to allergen 
extracts in the diagnosis of allergic diseases are: 
- the possibility to produce highly standardized quantifiable reagents for 
diagnostic applications in vivo and in vitro 
- an excellent specificity, reaching 100% in most of the published studies 
- a good safety, as side effects are very rare due to the quantifiable amount of 
protein applied 
- the possibility to investigate a single allergen instead of complex mixtures of 
allergens present in extracts, allowing insights into the epidemiologic and 
functional role of single molecules in allergic conditions 
 
Another important use of recombinant allergens might be their applications in specific 
immunotherapy with the possibility to manipulate the coding sequences of allergens 
to produce hypoallergenic variants, e.g. molecules retaining the important structural 
features for the induction of T-cell-mediated immune responses but lacking the 
capability to bind IgE. Especially in patients with mould allergy, the possiblities of 
immunotherapy are still very disappointing (44-46). Mostly due to the lack of 
standardization of the now available extracts, the use of recombinant allergens may 
substantially contribute to a improvement of immunotherapy. 
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There are also disadvantages in the use of recombinant allergens: 
- for complex allergenic sources like moulds, a panel of multiple recombinant 
allergens is needed to reach a sufficient sensitivity in the detection of patients 
with different sensitization patterns, limiting the use of recombinant allergens 
for routine skin tests 
- the allergenicity of recombinant allergens in vivo is lower than that of natural 
allergens due to the fact that possibly not all of the relevant allergens are 
contained in the panel of recombinant allergens used 
- the costs for the preparation of recombinant allergens are still substantially 
higher than for the production of allergen extracts. However this will change 
within the next years due to the important progress made in the industrialized 
production of recombinant proteins as e.g. already widely used for other drugs 
such as insulin. 
- due to legal and ethical restrictions the wide use of recombinant allergens in 
vivo is still limited in many nations. All these proteins have to be synthesized 
under ‘good manufacturing conditions’ (GMP-like) which costs substantially 
and still limits the use of these proteins in clinical work and for research use. 
 
In conclusion, our skin prick test study showed a high reliability for Alta1 to detect Alt 
a - allergic patients. Sensitization against the other tested allergens seems to be 
either very low or the in vivo allergenicity of these proteins is reduced due to the 
manufacturing process. Further investigations and testing with recombinant mould 
allergens in large groups of preferential exclusive mould allergic patients are 
necessary to find out more about mould allergy and to discover more important 
allergens to finally profit from the benefits and advantages of recombinant allergens. 
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